XLO Insider Trading

Insider Ownership Percentage: 3.50%
Insider Buying (Last 12 Months): $8,370,715.96
Insider Selling (Last 12 Months): $0.00

Xilio Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Xilio Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Xilio Therapeutics Share Price & Price History

Current Price: $3.00
Price Change: Price Decrease of -0.01 (-0.33%)
As of 09/23/2022 04:59 PM ET

This chart shows the closing price history over time for XLO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Xilio Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/10/2021Bain Capital Life Sciences InvMajor ShareholderBuy25,000$9.65$241,250.00View SEC Filing Icon  
12/8/2021Bain Capital Life Sciences InvMajor ShareholderBuy13,458$9.62$129,465.96View SEC Filing Icon  
10/26/2021Rock Springs Capital ManagemenMajor ShareholderBuy500,000$16.00$8,000,000.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Xilio Therapeutics (NASDAQ:XLO)

64.66% of Xilio Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at XLO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Xilio Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2022State Street Corp15,690$46K0.0%-83.3%0.057%Search for SEC Filing on Google Icon
8/15/2022Laurion Capital Management LP142,900$0.42M0.0%N/A0.520%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC49,956$0.15M0.0%N/A0.182%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC75,300$0.22M0.0%N/A0.274%Search for SEC Filing on Google Icon
8/12/2022Northern Trust Corp12,900$38K0.0%-79.7%0.047%Search for SEC Filing on Google Icon
8/12/2022FMR LLC2,521,333$7.36M0.0%-2.7%9.178%Search for SEC Filing on Google Icon
7/27/2022Bailard Inc.36,632$0.11M0.0%N/A0.133%Search for SEC Filing on Google Icon
5/16/2022Deerfield Management Company L.P. Series C2,078,692$14.70M0.3%-3.5%7.567%Search for SEC Filing on Google Icon
5/16/2022State Street Corp93,861$0.66M0.0%+58.5%0.342%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.416,393$2.94M0.0%-1.8%1.516%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.299,756$2.12M0.0%-7.5%1.091%Search for SEC Filing on Google Icon
5/12/2022Monashee Investment Management LLC163,066$1.15M0.3%-23.9%0.594%Search for SEC Filing on Google Icon
5/11/2022Bank of New York Mellon Corp21,029$0.15M0.0%+47.7%0.077%Search for SEC Filing on Google Icon
5/11/2022JPMorgan Chase & Co.4,844$34K0.0%-58.5%0.018%Search for SEC Filing on Google Icon
2/15/2022Davidson Kempner Capital Management LP29,000$0.46M0.0%N/A0.109%Search for SEC Filing on Google Icon
2/14/2022Deerfield Management Company L.P. Series C2,154,061$33.74M0.7%N/A8.078%Search for SEC Filing on Google Icon
2/14/2022Ghisallo Capital Management LLC30,000$0.48M0.0%N/A0.113%Search for SEC Filing on Google Icon
2/14/2022Soleus Capital Management L.P.477,495$7.64M0.8%N/A1.791%Search for SEC Filing on Google Icon
2/11/2022Granite Point Capital Management L.P.10,000$0.16M0.0%N/A0.038%Search for SEC Filing on Google Icon
2/9/2022AJU IB Investment Co. Ltd.667,742$10.68M14.9%N/A2.504%Search for SEC Filing on Google Icon
2/8/2022Northern Trust Corp63,034$1.01M0.0%N/A0.236%Search for SEC Filing on Google Icon
2/7/2022Monashee Investment Management LLC214,253$3.43M0.8%N/A0.803%Search for SEC Filing on Google Icon
2/7/2022RiverVest Venture Management LLC1,441,444$23.06M16.5%N/A5.406%Search for SEC Filing on Google Icon
2/2/2022New York State Common Retirement Fund5,568$89K0.0%N/A0.021%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Xilio Therapeutics logo
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Read More on Xilio Therapeutics

Today's Range

Now: $3.00
Low: $2.88
High: $3.04

50 Day Range

MA: $2.68
Low: $2.07
High: $3.44

52 Week Range

Now: $3.00
Low: $2.01
High: $27.95

Volume

837 shs

Average Volume

85,907 shs

Market Capitalization

$82.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Xilio Therapeutics?

Xilio Therapeutics' top insider shareholders include:
  1. Bain Capital Life Sciences Inv (Major Shareholder)
  2. Rock Springs Capital Managemen (Major Shareholder)
Learn More about top insider investors at Xilio Therapeutics.

Who are the major institutional investors of Xilio Therapeutics?

Xilio Therapeutics' top institutional investors include:
  1. FMR LLC — 9.18%
  2. Laurion Capital Management LP — 0.52%
  3. Renaissance Technologies LLC — 0.27%
  4. Millennium Management LLC — 0.18%
  5. Bailard Inc. — 0.13%
  6. State Street Corp — 0.06%
Learn More about top institutional investors of Xilio Therapeutics stock.

Which major investors are selling Xilio Therapeutics stock?

In the last quarter, XLO stock was sold by these institutional investors:
  1. State Street Corp
  2. FMR LLC
  3. Northern Trust Corp

Which major investors are buying Xilio Therapeutics stock?

Within the last quarter, XLO stock was acquired by institutional investors including:
  1. Laurion Capital Management LP
  2. Renaissance Technologies LLC
  3. Millennium Management LLC
  4. Bailard Inc.
In the previous year, these company insiders have bought Xilio Therapeutics stock:
  1. Bain Capital Life Sciences Inv (Major Shareholder)
  2. Rock Springs Capital Managemen (Major Shareholder)
Learn More investors buying Xilio Therapeutics stock.